Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Santa Monica, California + 5 more

Conditions: Alcohol Use Disorder
Interventions: Virtual Practice Facilitation with e-Learning, Virtual Practice Facilitation without e-Learning; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions: Administration of AZD6738; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Nicotine Dependence
Interventions: Sleep Advancement Counseling, General Health Information; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Melanoma
Interventions: Intetumumab, Dacarbazine, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more

Conditions: Healthy Volunteers
Interventions: PC14586, Rabeprazole, Famotidine; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Breast Cancer
Interventions: HKI-272, trastuzumab; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 6
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 3 more

Conditions: Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Aortic Arch Dissection
Interventions: CAAA and TAAA Arm, Aortic Arch Aneurysm Arm; Device
Lead sponsor: Gustavo S Oderich; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2032
U.S. locations: 3
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Falls, Motor Imagery, Multiple Sclerosis, Balance, Fatigue
Interventions: Motor Imagery as compared to physical practice for balance tasks; Other
Lead sponsor: Dominican University New York; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Hepatic Impairment
Interventions: BMS-986263; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
Interventions: Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth; Device · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: [¹⁴C]-LOXO-783, LOXO-783; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infection
Interventions: Emtricitabine/tenofovir disoproxil; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Anorexia Nervosa
Interventions: Narrative Medicine (NM) Workshop Series; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Carcinoma
Interventions: Best Practice, Communication Intervention, Interview; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 1,680 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions: AZD3470, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Brain Injuries, Traumatic, Rehabilitation
Interventions: Bilingual Brain Injury Education and outpatient Navigation for Hispanic families; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Colorado Springs, Colorado • Portland, Oregon • Dallas, Texas + 2 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: ERAS-007, ERAS-601; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more

Conditions: Solid Tumors, Breast Cancer, Cowden Syndrome
Interventions: BGT226; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Las Vegas, Nevada • San Antonio, Texas

Conditions: Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Interventions: ABBV-525; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more

Conditions: Melanoma
Interventions: Decitabine, Pegylated Interferon Alpha-2b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Haematological Malignancies
Interventions: AS703569; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Opioid Use Disorder
Interventions: Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg; Drug
Lead sponsor: Akyso Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Millcreek, Utah

Search by objective public record fields.

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Facilitating Alcohol Screening and Treatment (FAST)

AZD6738 First Time in Patient Multiple Ascending Dose Study

Examination of Sleep, Smoking Cessation, and Cardiovascular Health

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft

The Effect of Motor Imagery on Balance in Persons With Multiple Sclerosis

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

PopSci CHW4CervixHealth

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Factors Affecting PrEP Adherence

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Brain Injury Education and Outpatient Navigation-1stBIEN

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

iSTEP-N 101b: Pharmacokinetics and Safety Study of iSTEP-N Implant vs Monthly Vivitrol in Healthy Volunteers